Do you have a kidney transplant? Have you been diagnosed with recurrent Immunoglobulin A nephropathy (IgAN) or Focal Segmental Glomerulosclerosis (FSGS)? If so, this study may be of interest to you.

Are you a nurse in Saudi Arabia? We want to hear from you! Join our UNC study to share your thoughts on using genetics in nursing. Your feedback will help shape better nursing education and support your daily work.

The purpose of this immunotherapy study is to compare two different chemotherapy treatments administered before breast cancer surgery to see which has the better outcome.

Do you suffer from migraines? Are you interested in helping with migraine research?

Have you previously been screened for lung cancer? Or are you currently scheduled for a lung cancer screening? We are looking for Black/African American men and women between the ages of 50-80 to participate in a study about lung cancer. Compensation is provided.

Do you have a blood cancer or have received a stem cell transplant and have been diagnosed with a respiratory infection? If so, you might be eligible to take part in a study to see if an experimental treatment is effective at reducing the severity of the respiratory infection.

An important goal of this study is to evaluate the length of time cancer is not growing or spreading in participants when treated with zanzalintinib compared to everolimus. In addition, this study will also evaluate if zanzalintinib can shrink tumors and help participants live longer as compared to everolimus. This information will help researchers learn if zanzalintinib can be used to treat neuroendocrine cancer.

Are you a stroke survivor living with arm or hand weakness? Join our research study to help us learn how your brain talks to your muscles. This study involves just one visit with safe, non-invasive brain stimulation and easy movement tasks. Your help could make a big difference in stroke recovery research.

The goal of this research study is to test a new study treatment for a specific type of stomach cancer. It is focused on people whose tumors are CLDN18.2 positive, PD-L1 positive, and HER2 negative. This new study treatment has 3 parts: 1. A study drug called zolbetuximab 2. Another study drug called pembrolizumab 3. Standard chemotherapy (mFOLFOX or CAPOX) Researchers want to know if this combination is safe and if it works better than current treatments for people living with this specific type of stomach cancer

Have you been diagnosed with GCB Subtype of Diffuse LargeB-cell Lymphoma (DLBCL)? If so, you may be able to take part in a research study looking at Evaluating the Efficacy and Safety of Zilovertamab Vedotin (MK-2140) Plus R-CHP Versus Polatuzumab Vedotin Plus R-CHP in Treatment-naïve Participants With GCB Subtype of Diffuse Large B-cell Lymphoma (DLBCL